TNF and cardiovascular disorder: In another clinical trial that examined the 5-year cardiovascular events in patients with psoriasis, which was associated with cardiovascular disease, anti-TNF-α antibody therapy was shown to significantly reduce the cardiovascular risk compared with other treatments [70].